semaglutide 2.4 mg for Obesity

"Semaglutide 2.4 mg is frequently used to help patients manage their weight over the long term. However, it can also be used as part of a treatment plan that includes a reduced-calorie diet, exercise, and managing at least one other weight-related condition."

"The first semaglutide 2.4 mg clinical trial was completed in 2018 at the Novo Nordisk Investigational Site. So far, 123 trials have been completed in total. There are currently 59 actively recruiting trials, with a large number of these studies taking place in Saint Louis, Missouri."

"Since 2018, semaglutide 2.4 mg has been the subject of clinical research with the first trial sponsored by Novo Nordisk A/S. The Phase 4 drug approval was received following the first study in 2018, which involved 1387 patients. As of now, there are 59 live studies being conducted for semaglutide 2.4 mg across 711 cities in 55 countries."

"The pharmaceutical company leading this study, Novo Nordisk A/S, has announced that the primary outcome will be change in body weight from the start of the study (week 0) to the end of treatment (week 68). Additionally, this trial will be measuring if patients achieve a 5% or greater reduction in body weight (yes/no), change in pain medication (dose), and change in WOMAC stiffness score (points)."

"Semaglutide 2.4 mg is in Phase 3 clinical trials, signifying that while there is efficacy data, there are also multiple rounds of safety data. Because of this, our team has given it a score of 3."

"This specific trial is not enrolling patients at the moment, as indicated by the clinicaltrials.gov website. The listing was created on October 1st, 2021 and was last edited June 21st, 2022. Even though this trial has closed recruitment, there are 1,754 other trials that are still recruiting patients."